Sara Fritzell

Title: The Innovative Contributions of Sara Fritzell

Introduction

Sara Fritzell is a prominent inventor based in Lund, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific polypeptides. With a total of nine patents to her name, her work has the potential to impact medical treatments and therapies.

Latest Patents

One of her latest patents is focused on bispecific polypeptides against CD137. This invention provides bispecific polypeptides that include a first binding domain, designated B1, which specifically binds to CD137, and a second binding domain, designated B2, which binds to a tumor cell-associated antigen. Additionally, the invention includes pharmaceutical compositions of these bispecific polypeptides and their uses in medicine. Another notable patent involves bispecific polypeptides, such as bispecific antibodies, which comprise a first binding domain that specifically binds to a first T cell target and a second binding domain that binds to a different T cell target. This invention also encompasses compositions of these bispecific polypeptides, along with methods and uses in various applications.

Career Highlights

Sara has worked with notable companies in the biotechnology sector, including Alligator Bioscience AB and Aptevo Research and Development LLC. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research.

Collaborations

Sara has collaborated with esteemed colleagues such as Peter Ellmark and Christina Furebring. These partnerships have fostered an environment of innovation and creativity in her work.

Conclusion

Sara Fritzell's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments and therapies.